Form 4: Tonix Pharmaceuticals Director Sells Fractional Shares After Reverse Stock Split
SEC Form 4 Filing
Adeoye Y. Olukotun, a director at Tonix Pharmaceuticals, disposed of 0.812 common stock shares due to an involuntary sale of fractional shares following a reverse stock split.
Summary
- On June 10, 2024, Adeoye Y. Olukotun, a director of Tonix Pharmaceuticals Holding Corp., disposed of 0.812 shares of common stock.
- The transaction was an involuntary sale of fractional shares resulting from a reverse stock split.
- The shares were sold at a price of $1.91 per share.
- Following the transaction, Olukotun directly owns 0 shares of Tonix Pharmaceuticals Holding Corp.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding a small transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC for insiders (directors, officers, and principal stockholders) of publicly traded companies, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders due to the small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of transaction: Director Adeoye Y. Olukotun disposed of shares. |
| 02/28/2025 | Signature date of Attorney-in-Fact Jessica Morris. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.